CRT Appoints Board Member
This article was originally published in Scrip
Cancer Research Technology (CRT) has appointed Dr. Deborah Harland to its board as non-executive director. Deborah, who has held various roles in business development, clinical development and medical affairs, is currently a partner at the corporate venture capital arm of GlaxoSmithKline, SR One. She is also on the board of various biotech companies, in which SR One has invested, including Mission Therapeutics.
You may also be interested in...
How to make the most of the wealth of raw data in pharmaceutical R&D is an increasing challenge for the industry. The digital revolution is already having an impact in areas like clinical trials, and pharma is also starting to embrace new technologies in drug discovery.
Technology advancement has brought a wave of change in healthcare, with an increasing number of key pharma players now recognizing the potential of digital – particularly in clinical trials.
This week's roundup includes high-level appointments by Five Prime Therapeutics, Depomed and Gilead Sciences and board appointments by Verseon, Arix Bioscience, and Corbus Pharmaceuticals.